Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar;34(1):53-74.
doi: 10.1007/s10555-014-9540-2.

Targeted immune therapy of ovarian cancer

Keith L Knutson  1 , Lavakumar Karyampudi, Purushottam Lamichhane, Claudia Preston
Affiliations
Review

Targeted immune therapy of ovarian cancer

Keith L Knutson et al. Cancer Metastasis Rev. 2015 Mar.

Retraction in

Abstract

Clinical outcomes, such as recurrence-free survival and overall survival, in ovarian cancer are quite variable, independent of common characteristics such as stage, response to therapy, and grade. This disparity in outcomes warrants further exploration and therapeutic targeting into the interaction between the tumor and host. One compelling host characteristic that contributes both to the initiation and progression of ovarian cancer is the immune system. Hundreds of studies have confirmed a prominent role for the immune system in modifying the clinical course of the disease. Recent studies also show that anti-tumor immunity is often negated by immune regulatory cells present in the tumor microenvironment. Regulatory immune cells also directly enhance the pathogenesis through the release of various cytokines and chemokines, which together form an integrated pathological network. Thus, in the future, research into immunotherapy targeting ovarian cancer will probably become increasingly focused on combination approaches that simultaneously augment immunity while preventing local immune suppression. In this article, we summarize important immunological targets that influence ovarian cancer outcome as well as include an update on newer immunotherapeutic strategies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Immune mediators are involved in initiating ovarian cancer
Figure 2
Figure 2
The immune system favors tumor progression in ovarian cancer
Figure 3
Figure 3
The TNF network contributes to ovarian cancer pathogenesis
See this image and copyright information in PMC

Similar articles

  • Immunity and immune suppression in human ovarian cancer.
    Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Preston CC, et al. Immunotherapy. 2011 Apr;3(4):539-56. doi: 10.2217/imt.11.20. Immunotherapy. 2011. PMID: 21463194 Free PMC article.
  • The immune system in the pathogenesis of ovarian cancer.
    Charbonneau B, Goode EL, Kalli KR, Knutson KL, Derycke MS. Charbonneau B, et al. Crit Rev Immunol. 2013;33(2):137-64. doi: 10.1615/critrevimmunol.2013006813. Crit Rev Immunol. 2013. PMID: 23582060 Free PMC article. Review.
  • Immunotherapy in ovarian cancer.
    Krishnan V, Berek JS, Dorigo O. Krishnan V, et al. Curr Probl Cancer. 2017 Jan-Feb;41(1):48-63. doi: 10.1016/j.currproblcancer.2016.11.003. Epub 2016 Nov 15. Curr Probl Cancer. 2017. PMID: 28169004 Review.
  • Preface.
    Tainsky MA, Morris RT. Tainsky MA, et al. Cancer Metastasis Rev. 2015 Mar;34(1):3. doi: 10.1007/s10555-014-9548-7. Cancer Metastasis Rev. 2015. PMID: 25648358 No abstract available.
  • Immunotherapy in Ovarian Cancer.
    Wang W, Liu JR, Zou W. Wang W, et al. Surg Oncol Clin N Am. 2019 Jul;28(3):447-464. doi: 10.1016/j.soc.2019.02.002. Epub 2019 Apr 5. Surg Oncol Clin N Am. 2019. PMID: 31079799 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. A Cancer Journal for Clinicians. 2013;63(1):11–30. doi:10.3322/caac.21166. - PubMed
    1. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC. Current management strategies for ovarian cancer. Mayo Clinic Proceedings. 2007;82(6):751–770. doi:10.4065/82.6.751. - PubMed
    1. Cannistra SA. Cancer of the ovary. The New England Journal of Medicine. 2004;351(24):2519–2529. doi:10.1056/NEJMra041842. - PubMed
    1. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology. 2003;21(17):3194–3200. doi:10.1200/JCO.2003.02.153. - PubMed
    1. Vaughan S, Coward JI, Bast RC, Jr., Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer. 2011;11(10):719–725. doi:10.1038/nrc3144. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources